MYC and cancer: Furthermore, across many different types of cancers there exists a number of oncogenes and tumour suppressor genes, many of which have yet to be targeted by anti-cancer therapies, including TP53 and MYC: the presence of this “undruggable genome” further contributes to tumour cell heterogeneity and hence drug resistance (Vasan et al., 2019).